Liberia, Guinea & DRC Ebola Response Program (ERP)

Project Overview
Provide guidance and oversight in the administration of disbursements for local resources and services including: recruitment and hiring of on-the-ground resources; the procurement and payment of expenses in support of clinical studies; facilitation, coordination, and payment of travels and meetings; and assistance in the management of operations in collaboration with Leidos Biomed and the University of Minnesota.
Funding Agency: NIAID DCR
Project Description
The NIAID Division of Clinical Research (DCR) supports clinical research to control and prevent diseases caused by virtually all infection agents. This includes basic and applied research to develop and evaluate therapeutics, vaccines, and diagnostics. In support of the viral hemorrhagic fevers (VHF) and other emerging infectious disease initiatives, Leidos Biomed in partnership with TMG provides management and oversight for the conduct of clinical research studies in Liberia and Guinea. In this time-sensitive initiative, TMG provides guidance and oversight in the administration of disbursements for local resources and services including: recruitment and hiring of on-the-ground resources; the procurement and payment of expenses in support of clinical studies; facilitation, coordination, and payment of travels and meetings; and assistance in the management of operations in collaboration with Leidos Biomed and the University of Minnesota.
The initiative provides on-the-ground disbursement services needed to respond to an urgent health crisis. Such rapid response is required to conduct clinical research during the Zaire Ebola outbreak and to initiate data collection to inform future treatment and prevention options and research design.
Implementation
2014-2019
Key Accomplishments
Antibody manufactured at Frederick National Laboratory receives FDA approval to treat Ebola virus disease
The PALM study was organized by an international research consortium coordinated by the World Health Organization and was led and funded by NIAID and the DRC’s National Institute for Biomedical Research and Ministry of Health. The consortium included the Frederick National Laboratory, Doctors Without Borders, the International Medical Corps, The Mitchell Group, and the Alliance for International Medical Action.